Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
Effects of Canagliflozin on Serum Magnesium in Patients With Type 2 Diabetes Mellitus: A Post Hoc Analysis of Randomized Controlled Trials.
复制标题
DOI：
10.1007/s13300-017-0232-0
复制
发表时间：
2017-04
期刊：
影响因子：
--
通讯作者：
Desai M
中科院分区：
文献类型：
--
作者：
Gilbert RE;Mende C;Vijapurkar U;Sha S;Davies MJ;Desai M
本研究的目的是评价卡格列净（一种钠葡萄糖协同转运蛋白2抑制剂）对2型糖尿病低镁血症患者血清镁的影响。该事后分析基于4项卡格列净安慰剂对照研究（N = 2313）的汇总数据。评估了基线血清镁<0.74 mmol/L的患者在第26周达到血清镁≥0.74 mmol/L的比例。第26周时，在基线血清镁<0.74 mmol/L（17.0%和19.0% vs 3.9%）和≥0.74 mmol/L（4.9%和7.0% vs −1.4%）的患者中，与安慰剂相比，卡格列净100和300 mg使血清镁升高。卡格列净100 mg和300 mg组与安慰剂组相比，基线血清镁<0.74 mmol/L的患者在第26周时血清镁≥0.74 mmol/L的患者更多（74.1%和80.6% vs 28.8%）。卡格列净与2型糖尿病低镁血症患者的血清镁正常化相关，可能导致心脏代谢结局改善。 临床试验注册：ClinicalTrials.gov标识符、NCT 01081834、NCT 01106677、NCT 01106625、NCT 01106690。
The objective of this study was to evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on serum magnesium in hypomagnesemic patients with type 2 diabetes. This post hoc analysis was based on pooled data from four placebo-controlled studies of canagliflozin (N = 2313). The proportion of patients with baseline serum magnesium <0.74 mmol/L who achieved serum magnesium ≥0.74 mmol/L at week 26 was evaluated. At week 26, canagliflozin 100 and 300 mg increased serum magnesium versus placebo in patients with baseline serum magnesium <0.74 mmol/L (17.0% and 19.0% vs 3.9%) and ≥0.74 mmol/L (4.9% and 7.0% vs −1.4%). More patients with baseline serum magnesium <0.74 mmol/L had serum magnesium ≥0.74 mmol/L at week 26 with canagliflozin 100 and 300 mg versus placebo (74.1% and 80.6% vs 28.8%). Canagliflozin was associated with normalization of serum magnesium in hypomagnesemic patients with type 2 diabetes, potentially leading to improved cardiometabolic outcomes. Clinical trial registration: ClinicalTrials.gov Identifiers, NCT01081834, NCT01106677, NCT01106625, NCT01106690.